Phesi Launches Integrated SaaS Platform


Expected to improve patient centricity, simplify clinical development process through commercialization

Phesi, a provider of patient-centric data analytics, has officially launched its branded AI-driven “Trial Accelerator” platform to facilitate real-time scenario modeling across patient, endpoint, country, key opinion leader (KOL), and investigator site allocation. Essentially, the software-as-a service (SaaS) platform allows for clinical development personnel to optimize study design and simulate trial outcomes.

The company’s new platform leverages clinical study data, including control arm data, to accelerate product development and commercialization. The methods and AI models used have been created and validated over the past 15 years and are exclusive to Phesi, the provider notes. The platform powers clinical development decision making by connecting the design to execution, and allowing study teams to design smarter trials with the goal of developing faster cures. Phesi partners will also benefit from access to real-world data by being able to create digital patient profiles, digital twins and digital control arms (DCA), including external control arms.

“The industry needs a way to build the bridge between data and insight to deliver truly patient-centric trials. After years of upheaval from COVID-19 and with global events having huge impact on clinical development, being able to predict outcomes and minimize both risk and impact on patients, is critical,” says Gen Li, PhD, CEO and founder of Phesi. Dr. Li also noted a disconnect in the sense that currently, functions of clinical trials are siloed, while patient profiles are not always understood.

Related Videos
© 2024 MJH Life Sciences

All rights reserved.